Ra, which has a relatively long half-life (t 1/2 ) of 1,600 years, the only naturally occurring isotopes of actinium are 227 Ac (t 1/2 = 21.8 years), which comes from the decay of the already rare 235 U, and 228 Ac (t 1/2 = 6.1 hours), a furtive decay product of 232 Th. The elusive nature of Ac, combined with two world wars in the first half of the twentieth century, resulted in the knowledge of no new isotopes until 1947, though 32 have now been identified and 60 more are expected to exist. Unfortunately, this profusion of new man-made Ac isotopes synthesized since the 1950's has not produced any long-lived actinium atoms, they all actively decay in a few hours at best, with the exception of Po. The design of in vivo stable carriers able to scavenge both actinium and its alpha cascade raises hope for highly efficient cancer therapies with no side effects. Various strategies are under development, among which the encapsulation within nanoparticles seems most promising, whereby tumour delivery of 225 Ac through a lanthanide-based 'nanosafe' could neutralize metastases without leaving radioactive traces in the patient 4 . Finally, Cerenkov luminescence imaging of targeted tissues using the in situ decay of 225 Ac and its daughter products has recently brought to light the formidable theranostic potential of 225 Ac-based radiopharmaceuticals 5 . The quest for an efficient and silent, but traceable cancer treatment could turn into reality thanks to an element that has been largely overlooked since its discovery. Studies of actinium have taken researchers through the realms of radiochemistry, nuclear science, particle physics, medicine, and more recently nanomaterial design, underlining how
